CLAIMS

WHAT IS CLAIMED IS:

1. Use of:

(a) tirapazamine;

(b) combretastatin A4 phosphate; and

(c) an immune checkpoint inhibitor of PD-1 in the manufacture of a medicament for a combination therapy for enhancing an immune response to a solid tumor in a subject, wherein the immune checkpoint inhibitor is an antibody.

2. The use of claim 1, wherein the immune checkpoint inhibitor is a monoclonal antibody.

3. The use of claim 2, wherein the monoclonal antibody is nivolumab or pembrolizumab.

4. The use of claim 1, wherein the solid tumor is a tumor selected from the group consisting of: hepatocellular carcinoma, cholangiocarcinoma, metastatic colorectal cancer in liver, lung cancer, breast cancer, colorectal cancer, bladder cancer, head and neck cancer, ovarian cancer, and pancreatic cancer.

5. A kit for use in combination therapy for enhancing an immune response to a solid tumor in a subject, the kit comprising:

(a) tirapazamine;

(b) combretastatin A4 phosphate; and

(c) an immune checkpoint inhibitor of PD-1, wherein the immune checkpoint inhibitor is an antibody.

6. The kit of claim 5, wherein the immune checkpoint inhibitor is a monoclonal antibody.

7. The kit of claim 6, wherein the monoclonal antibody is nivolumab or pembrolizumab.